Ubs Group Ag Fate Therapeutics Inc Transaction History
Ubs Group Ag
- $555 Billion
- Q2 2025
A detailed history of Ubs Group Ag transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Ubs Group Ag holds 962,672 shares of FATE stock, worth $1.45 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
962,672
Previous 1,551,081
37.94%
Holding current value
$1.45 Million
Previous $1.23 Million
12.0%
% of portfolio
0.0%
Previous 0.0%
Shares
33 transactions
Others Institutions Holding FATE
# of Institutions
150Shares Held
83.3MCall Options Held
179KPut Options Held
13.4K-
Redmile Group, LLC San Francisco, CA12.9MShares$19.4 Million1.75% of portfolio
-
Black Rock Inc. New York, NY10.1MShares$15.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.77MShares$13.2 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.54MShares$6.86 Million0.0% of portfolio
-
Jpmorgan Chase & CO New York, NY3.4MShares$5.13 Million0.0% of portfolio
About FATE THERAPEUTICS INC
- Ticker FATE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,000,304
- Market Cap $146M
- Description
- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...